使用美国安进地诺单抗的注意事项

Osteoporosis is a bone disease that affects 40% of people with TDT (an inherited congenital blood disorder that results in reduced production of hemoglobin and red blood cells) and is one of the most prevalent comorbidities associated with the disease. Denosumab developed by Amgen in the United States has been approved for marketing, approved for the treatment of breast cancer, and also approved for the prevention of bone-related events of bone metastasis of solid tumors.

Patients need to know the precautions for drug treatment. What are the precautions for using Amgen denosumab?

Hypocalcemia must be corrected before patients are initiated on denosumab. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels (such as phosphorus and magnesium) is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D.

Patients who are concurrently taking immunosuppressants or have compromised immune systems may be at increased risk of serious infections, and physicians need to fully consider the benefit-risk ratio before prescribing denosumab to these patients. For patients who develop serious infections while taking denosumab, physicians should evaluate the need to continue treatment with denosumab.

Osteonecrosis of the jaw (which can occur spontaneously) usually occurs with tooth extraction and local infection that delays healing. Routine oral examination should be performed before starting treatment with Amgen denosumab, and good oral hygiene should be maintained after starting treatment. If a patient develops osteonecrosis of the jaw, treatment for the osteonecrosis of the jaw may actually aggravate the condition. At this time, consideration should be given to discontinuing Amgen.

Recommended related hot articles: /newsDetail/85809.html